Tumor markers in the diagnosis, monitoring and therapy of pancreatic cancer: state of the art.
The present review focuses on the utility of serum tumor markers in screening, diagnosis, prognosis and monitoring of pancreatic cancer. Serum determination of all tumor markers studied offers no help in screening or early diagnosis of pancreatic cancer. For diagnosis, blood group-related antigens, in particular CA 19-9, are considered the best indicators of this neoplasm. However, as occurs with other glycoproteic tumor markers, the circulating levels of CA 19-9 are significantly influenced by jaundice, probably because its liver metabolism is reduced. Therefore, the finding of elevated CA 19-9 levels in jaundiced patients has to be evaluated with caution. Since pancreatic cancer recurrences are not susceptible to treatment, the clinical role of widespread use of tumor marker determination in follow-up programs is limited and calls for a critical evaluation.
Plebani
M
M
Department of Laboratory Medicine, University of Padova, Italy.
Basso
D
D
Panozzo
M P
MP
Fogar
P
P
Del Favero
G
G
Naccarato
R
R
D000951:Antigens, Neoplasm / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D001789:Blood Group Antigens / Q000097:blood / Q000737:chemistry; D018395:CA-19-9 Antigen / Q000097:blood*; D002240:Carbohydrate Sequence; D004798:Enzymes / Q000097:blood; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D008969:Molecular Sequence Data; D008991:Monitoring, Physiologic; D010190:Pancreatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000628:therapy*; D011379:Prognosis; D012008:Recurrence
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D001789:Blood Group Antigens; D018395:CA-19-9 Antigen; D004798:Enzymes; D006023:Glycoproteins; C031192:oncofetal antigens